Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
AgomAb Therapeutics NV (AGMB) had Consolidated Net Income/Loss of -70.75M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-70.75M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-70.75M |
|
|
Consolidated Net Income/Loss |
-70.75M |
-- |
|
-- |
|
-- |
|
0.44M |
|
0.44M |
|
-162.00 |
|
-162.00 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|